Adaptive designs in clinical trials: why use them, and how to run and report them.

Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T. · 2018

Read Adaptive designs in clinical trials: why use them, and how to run and report them. by Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5830330.txt.

Introduction

Pallmann and co-authors explain adaptive designs for clinical trials. An adaptive trial can change course as results build up. All changes follow rules set in advance. Such trials can save time, money, and participants.

Uptake lags the methods literature, partly from fuzzy terms. The tutorial sorts what adaptive design truly covers. It weighs gains against pitfalls in plain terms. Practical hurdles include funding, ethics review, and drug supply. Reporting duties get their own guidance. The authors stress that investigators must grasp the design's limits. Readers get a working brief for running flexible trials well.

Catalog record

CREATORPallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE80 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5830330

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Adaptive designs in clinical trials: why use them, and how to run and report them By Philip Pallmann, Alun W Bedding, Babak Choodari-Oskooei, Munyaradzi Dimairo, Laura Flight, Lisa V Hampson, Jane Holmes, Adrian P Mander, Lang’o Odondi, Matthew R Sydes, Sofía S Villar, James M S Wason Published in: BMC Medicine DOI: 10.1186/s12916-018-1017-7 ABSTRACT Abstract Adaptive designs can make clinical trials more flexible by utilising results accumulating in the trial to modify the trial’s course in accordance with pre-specified rules. Trials with an adaptive design are often more efficient, informative and ethical than trials with a traditional fixed design since they often make better use of resources such as time and money, and might require fewer participants. Adaptive designs can be applied across all phases of clinical research, from early-phase dose escalation to confirmatory trials. The pace of the uptake of adaptive designs in clinical research, however, has remained well behind that of the statistical literature introducing new methods and highlighting their potential advantages. We speculate that one factor contributing to this is that the full range of adaptations available to trial designs, as well as their goals, advantages and limitations, remains unfamiliar to many parts of the clinical community. Additionally, the term adaptive design has been misleadingly used as an all-encompassing label to refer to certain methods that could be deemed controversial or that have been inadequately implemented. We believe that even if the planning and analysis of a trial is undertaken by an expert statistician, it is essential that the investigators understand the implications of using an adaptive design, for example, what the practical challenges are, what can (and cannot) be inferred from the results of such a trial, and how to report and communicate the results. This tutorial paper provides guidance on key aspects of adaptive designs that are relevant to clinical triallists. We explain the basic rationale behind adaptive designs, clarify ambiguous terminology and summarise the utility and pitfalls of adaptive designs. We discuss practical aspects around funding, ethical approval, treatment supply and communication with stakeholders and trial participants. Our focus, however, is on the interpretation and reporting of results from adaptive design trials, which we consider vital for anyone involved in medical research. We emphasise the general principles of transparency and reproducibility and suggest how best to put them into practice. Keywords: Statistical methods, Adaptive design, Flexible design, Interim analysis, Design modification, Seamless design WHY, WHAT AND WHEN TO ADAPT IN CLINICAL TRIALS Traditionally, clinical trials have been run in three steps [1]: - The trial is designed. - The trial is conducted as prescribed by the design. - Once the data are ready, they are analysed according to a pre-specified analysis plan. This practice is straightforward, but clearly inflexible as it does not include options for changes that may become desirable or necessary during the course of the trial. Adaptive designs (ADs) provide an alternative. They have been described as ‘planning to be flexible’ [2], ‘driving with one’s eyes open’ [3] or ‘taking out insurance’ against assumptions [4]. They add a review–adapt loop to the linear design–conduct–analysis sequence (Fig. 1). Scheduled interim looks at the data are allowed while the trial is ongoing, and pre-specified changes to the trial’s course can be made based on analyses of accumulating data, whilst maintaining the validity and integrity of the trial. Such a priori planned adaptations are fundamentally different from unplanned ad hoc modifications, which are common in traditional trials (e.g. alterations to the eligibility criteria). [Figure: Schematic of a traditional clinical trial design with fixed sample size, and an adaptive design with pre-specified review(s) and adaptation(s)] Pre-planned changes that an AD may permit include, but are not limited to [5]: - refining the sample size - abandoning treatments or doses - changing the allocation ratio of patients to trial arms - identifying patients most likely to benefit and focusing recruitment efforts on them - stopping the whole trial at an early stage for success or lack of efficacy. Table 1 lists some well-recognised adaptations and examples of their use. Note that multiple adaptations may be used in a single trial, e.g. a group-sequential design may also feature mid-course sample size re-estimation and/or adaptive randomisation [6], and many multi-arm multi-stage (MAMS) designs are inherently seamless [7]. ADs can improve trials across all phases of clinical development, and seamless designs allow for a more rapid transition between phases I and II [8, 9] or phases II and III [10, 11]. [Table: Overview of adaptive designs with examples of trials that employed these methods] The defining characteristic of all ADs is that results from interim data analyses are used to modify the ongoing trial, without undermining its integrity or validity [12]. Preserving the integrity and validity is crucial. In an AD, data are repeatedly examined. Thus, we need to make sure they are collected, analysed and stored correctly and in accordance with good clinical practice at every stage. Integrity means ensuring that trial data and processes have not been compromised, e.g. minimising information leakage at the interim analyses [13]. Validity implies there is an assurance that the trial answers the original research questions appropriately, e.g. by using methods that provide accurate estimates of treatment effects [14] and correct p values [15–17] and confidence intervals (CIs) for the treatment comparisons [18, 19]. All these issues will be discussed in detail in subsequent sections. The flexibility to make mid-course adaptations to a trial is not a virtue in itself but rather a gateway to more efficient trials [20] that should also be more appealing from a patient’s perspective in comparison to non-ADs because: - Recruitment to futile treatment arms may stop early. - Fewer patients may be randomised to a less promising treatment or dose. - On average, fewer patients may be required overall to ensure the same high chance of getting the right answer. - An underpowered trial, which would mean a waste of resources, may be prevented. - A better understanding of the dose–response or dose–toxicity relationship may be achieved, thus, facilitating the identification of a safe and effective dose to use clinically. - The patient population most likely to benefit from a treatment may be identified. - Treatment effects may be estimated with greater precision, which reduces uncertainty about what the better treatment is. - A definitive conclusion may be reached earlier so that novel effective medicines can be accessed sooner by the wider patient population who did not participate in the trial. ADs have been available for more than 25 years [21], but despite their clear benefits in many situations, they are still far from established in practice (with the notable exception of group-sequential methods, which many people would not think to recognise as being adaptive) for a variety of reasons. Well-documented barriers [22–29] include lack of expertise or experience, worries of how funders and regulators may view ADs, or indeed more fundamental practical challenges and limitations specific to certain types of ADs. We believe that another major reason why clinical investigators are seldom inclined to adopt ADs is that there is a lack of clarity about: - when they are applicable - what they can (and cannot) accomplish - what their practical implications are - how

Read the complete text